SPARC and neoplasm: Interestingly, among NSCLC patients with early tumor stage (I–II), the estimated overall survival was dramatically reduced from 80% to 10% when SPARC methylation levels passed from 0 to 300 and thereafter tended toward 0% for greater values (Figure 10, panel C).